GlassScriptPhysician profile
Karri Berlin
NPI 1619521606
$4,826.18
in general payments reported to CMS, 2019-2025
30 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,271 · 2024: $1,665 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,826.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,305.35 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $731.36 | 2023-2025 | Xifaxan, Trulance, Uceris |
| Regeneron Healthcare Solutions, INC. | $394.20 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $369.14 | 2023-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $272.56 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $197.31 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $188.72 | 2023-2025 | |
| Qol Medical, LLC | $185.15 | 2023-2024 | Sucraid, Sucraid |
| Novo Nordisk INC | $151.01 | 2025 | Wegovy |
| Celltrion USA INC. | $124.02 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $107.96 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $105.87 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $95.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $77.43 | 2023 | Dificid |
| Aimmune Therapeutics, INC. | $66.03 | 2024-2025 | Vowst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.47 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $59.05 | 2024 | Tremfya |
| Ironwood Pharmaceuticals, INC | $50.12 | 2024 | |
| Intercept Pharmaceuticals, INC. | $48.14 | 2024-2025 | |
| Lilly USA, LLC | $45.45 | 2024-2025 | Omvoh, Mounjaro |
| Exact Sciences Corporation | $32.02 | 2023-2025 | Cologuard Collection Kit |
| La Jolla Pharmaceutical Company | $30.10 | 2023 | Xerava |
| Pharmacosmos Therapeutics INC. | $18.71 | 2024 | Monoferric |
| Kci USA, INC. | $17.78 | 2023 | Prevena |
| Smith+Nephew, INC. | $17.21 | 2025 | Collagenase Santyl |
| W. L. Gore & Associates, INC. | $15.87 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Organon LLC | $15.45 | 2023 | Hadlima |
| Fresenius Kabi USA, LLC | $14.15 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $13.39 | 2023 | |
| Evoke Pharma, INC. | $13.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karri Berlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.